NCT05362409View on ClinicalTrials.gov

Study to Evaluate 5-ALA Combined With CV01 Delivery of Ultrasound in Recurrent High Grade Glioma

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

June 29, 2022

Primary Completion Date

December 3, 2024

Study Completion Date

February 3, 2025

Conditions
High Grade Glioma
Interventions
DRUG

5 Aminolevulinic Acid

5-aminolevulinic acid \[5-ALA\] administered orally 20 mg/kg every 4 weeks

DEVICE

CV01-delivered ultrasound

CV01-delivered ultrasound every 4 weeks

Trial Locations (3)

11042

Northwell, Lake Success

14226

Dent Neurosciences Research Center, Amherst

63110

Washington University School of Medicine in St.Louis, St Louis

Sponsors
All Listed Sponsors
lead

Alpheus Medical, Inc.

INDUSTRY

NCT05362409 - Study to Evaluate 5-ALA Combined With CV01 Delivery of Ultrasound in Recurrent High Grade Glioma | Biotech Hunter | Biotech Hunter